Tuesday, March 20th, 2018, Insilico Medicine, a Baltimore-based artificial intelligence company specializing in drug discovery, biomarker development and aging research announced the launch of Insilico Taiwan, a subsidiary focusing on the development and validation of generative adversarial networks(GANs) and reinforcement learning for medicinal chemistry applications.

The opening ceremony will coincide with the presentation of new research results about GAN architectures specifically designed for the generation of novel molecules with the desired set of molecular properties.

The ceremony will transpire on Wednesday, March 21st between 13:30 and 16:00 local time in the ballroom of the Regent Hotel, Taipei. The journalists and pharmaceutical companies are invited to attend the ceremony and meet the team of Insilico Taiwan.

"We are very happy to launch our R&D center in Taipei, where there is abundant talent in medicinal chemistry and biology and the working vertically-integrated drug discovery infrastructure. The recent advances of artificial intelligence will help to turn this infrastructure into the global pharmaceutical powerhouse. We would like to thank the Department of Commercialization of Biotechnology (DCB) for their support and effective collaboration in the application of AI to drug discovery", said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine and adjunct professor of the Buck Institute for Research on Aging.

Insilico Medicine is one of the first AI companies to combine the expertise in artificial intelligence applied to the cutting-edge medicinal chemistry and disease signature development and target identification with deep domain knowledge in and focus on aging and age-related diseases.

"I am happy to take the role of head of Insilico Taiwan and establish the local deep learning team. It will be integrated into the local drug discovery ecosystem and will help building the pharmaceutical industry of the future. Taiwan consistently demonstrated its leadership in technology with the examples in electronics industry and I am very happy to contribute to the effort to repeat these miracles in the pharmaceutical space", said Artur Kadurin, the head of Insilico Taiwan.

Very recently Insilico Medicine published series of research papers describing novel approaches in aging biomarker development using deep neural networks and got several new papers accepted in major scientific journals. Some of these results will be presented at the opening ceremony.